))
DME/Retina Edition: Top Headlines for Week of August 5, 2024
Manage episode 433131307 series 3560281
İçerik Healio tarafından sağlanmıştır. Bölümler, grafikler ve podcast açıklamaları dahil tüm podcast içeriği doğrudan Healio veya podcast platform ortağı tarafından yüklenir ve sağlanır. Birinin telif hakkıyla korunan çalışmanızı izniniz olmadan kullandığını düşünüyorsanız burada https://tr.player.fm/legal özetlenen süreci takip edebilirsiniz.
In this edition, sozinibercept combination therapy shows durability, comparable improvements with aflibercept and more. Read the full coverage here:
Sozinibercept combination therapy shows durability in patients with DME, neovascular AMD
VIDEO: Comparable improvements seen with aflibercept 8 mg vs. 2 mg in DME
DPP-IV, SGLT2 and GLP-1 drugs do not increase risk for diabetic macular edema
Eluminex doses first patient in phase 1b trial of EB-105 for diabetic macular edema
VIDEO: Port delivery system maintains visual, anatomic improvements in DME at 2 years
References:
Awh C. Port delivery system with ranibizumab for continuous treatment of diabetic macular edema: First readout of the phase 3 Pagoda trial year 2 results. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm.
Do D. Outcomes of patients with DME and baseline BCVA of 20/50 or worse or 20/40 or better treated with aflibercept 8 mg and 2 mg in the phase 2/3 PHOTON trial. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm.
Phu A, et al. J Diabetes Complications. 2024;doi:10.1016/j.jdiacomp.2024.108808.
Steinle NC. Durability of combination therapy of sozinibercept (OPT-302), an anti-VEGF-C/-D ‘trap’ with ranibizumab in nAMD or aflibercept in DME. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm.
118 bölüm
Paylaş
